Heike Keihack

Learn More
Gefitinib, a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been shown to induce autophagy as well as apoptosis in tumor cells. Yet, how to use autophagy and apoptosis to improve therapeutic efficacy of this drug against cancer remains to be explored. We reported here that MK-2206, a potent allosteric Akt inhibitor(More)
Gefitinib, a smallmolecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been shown to induce autophagy as well as apoptosis in tumor cells. Yet, how to use autophagy and apoptosis to improve therapeutic efficacy of this drugagainst cancer remains to be explored.We reportedhere thatMK-2206, apotent allosteric Akt inhibitor currently(More)
e13590 Background: Rational combination of 2 or more investigational compounds is a novel concept in oncology. We have entered phase I clinical development in patients with solid tumors with novel doublet combinations of dalotuzumab/MK-2206 and dalotuzumab/MK-0752. The preclinical rationale supporting one such combination of dalotuzumab and MK-2206 (an AKT(More)
  • 1